Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tate Thigpen

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Gynecologic Oncology|October 21, 2009
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group studyGini F Fleming, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|November 19, 2013
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paperThomas J Herzog, Deborah K Armstrong, Mark F Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsMartee L Hensley, Karen L Hagerty, Tarun Kewalramani, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
First-line therapy in ovarian cancer trialsTate Thigpen, Andreas duBois, Jessica McAlpine, et al.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Gynecologic Oncology|October 21, 2009
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group studyGini F Fleming, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|November 19, 2013
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paperThomas J Herzog, Deborah K Armstrong, Mark F Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsMartee L Hensley, Karen L Hagerty, Tarun Kewalramani, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Gynecologic Oncology|March 14, 2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group studyJanet S Rader, Michael W Sill, Jan H Beumer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
First-line therapy in ovarian cancer trialsTate Thigpen, Andreas duBois, Jessica McAlpine, et al.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 4